Company intelligence / Profile preview

OXiGENE, Inc.

South San Francisco, California, United Statesorpha.net ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

Developing vascular disrupting agents that selectively obstruct tumor blood supply without affecting normal tissues, leading to significant central tumor necrosis. Their lead compound ZYBRESTAT (fosbretabulin tromethamine/CA4P) was in clinical trials for various cancers

Therapeutic areas: OncologyOphthalmology
Modalities: Small moleculesVascular Disrupting Agents (VDAs)
Industry: Biotech

Drug pipeline

3 assets

fosbretabulin

2 more assets in the full pipeline.

Request access →

Partnerships

Symphony Capital Partners, L.P. (provided up to $40 million funding)

Beyond the preview

Go deeper on OXiGENE, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OXiGENE, Inc..

Explore the full profile